Features of the AHASR patients who were on anticoagulant/antiplatelet therapy at the time of diagnosis
| Variable . | n/N (%)* . |
|---|---|
| On ACG/APT therapy 1 mo before Dx | |
| Whole cohort | 32/93 (34.4) |
| >65 y | 29/72 (40.3) |
| ≤65 y | 3/21 (14.3) |
| Age at Dx (y), median (IQR) | 79 (73-86) |
| Male | 25/31 (80.7) |
| On ACGs† | 12/32 (37.5) |
| VKAs | 10/11 (90.9) |
| DOACs | 1/11 (9.1) |
| On APTs† | 22/32 (68.7) |
| Rationale for therapy‡ | |
| Previous arterial Ischemic event§ | 19/32 (59.4) |
| Previous venous thromboembolism | 3/32 (9.4) |
| Atrial fibrillation | 9/32 (28.1) |
| Primary prevention for CV risk | 3/32 (9.4) |
| Other║ | 4/32 (12.5) |
| Bleeding location at Dx¶ | |
| Mucocutaneous | 21/32 (65.6) |
| Muscular | 10/32 (31.2) |
| Urinary | 7/32 (21.9) |
| Digestive | 5/32 (15.6) |
| Retroperitoneal | 3/32 (9.4) |
| Thoracic | 3/32 (9.4) |
| Other# | 4/32 (12.5) |
| Required bypassing treatment at Dx | 24/31 (77.4) |
| rFVIIa | 11/21 (52.4) |
| aPCC | 7/21 (33.3) |
| Both | 3/21 (14.3) |
| Thromboembolic events after FVIII recovery | 2/32 (6.2) |
| Survival at the end of follow-up | 17/31 (54.8) |
| Variable . | n/N (%)* . |
|---|---|
| On ACG/APT therapy 1 mo before Dx | |
| Whole cohort | 32/93 (34.4) |
| >65 y | 29/72 (40.3) |
| ≤65 y | 3/21 (14.3) |
| Age at Dx (y), median (IQR) | 79 (73-86) |
| Male | 25/31 (80.7) |
| On ACGs† | 12/32 (37.5) |
| VKAs | 10/11 (90.9) |
| DOACs | 1/11 (9.1) |
| On APTs† | 22/32 (68.7) |
| Rationale for therapy‡ | |
| Previous arterial Ischemic event§ | 19/32 (59.4) |
| Previous venous thromboembolism | 3/32 (9.4) |
| Atrial fibrillation | 9/32 (28.1) |
| Primary prevention for CV risk | 3/32 (9.4) |
| Other║ | 4/32 (12.5) |
| Bleeding location at Dx¶ | |
| Mucocutaneous | 21/32 (65.6) |
| Muscular | 10/32 (31.2) |
| Urinary | 7/32 (21.9) |
| Digestive | 5/32 (15.6) |
| Retroperitoneal | 3/32 (9.4) |
| Thoracic | 3/32 (9.4) |
| Other# | 4/32 (12.5) |
| Required bypassing treatment at Dx | 24/31 (77.4) |
| rFVIIa | 11/21 (52.4) |
| aPCC | 7/21 (33.3) |
| Both | 3/21 (14.3) |
| Thromboembolic events after FVIII recovery | 2/32 (6.2) |
| Survival at the end of follow-up | 17/31 (54.8) |
Missing data were not considered.
ACGs, anticoagulants; APTs, antiplatelets; CV, cardiovascular; DOACs, direct oral anticoagulants; Dx, diagnosis; VKAs, vitamin K antagonists.
Unless otherwise specified.
Two patients were on ACG and APT therapy.
Six patients presented with more than 1 cause to indicate antithrombotic therapy.
Coronary (11), cerebrovascular (4), peripheral (5), mesenteric (1).
Aortic valve replacement (1), dilated cardiomyopathy (2), nonspecified (1).
Sixteen patients had bleedings in more than 1 site.
Retropharyngeal (1), nonspecified (3).